China’s National Medical Products Administration granted approval for Brii Biosciences’ combination of two antibodies to be used for at-risk groups. Shutterstock Images
China’s National Medical Products Administration granted approval for Brii Biosciences’ combination of two antibodies to be used for at-risk groups. Shutterstock Images

Coronavirus: China approves first local neutralising antibody cocktail for high-risk patients

  • Brii Biosciences says its therapy shows an 80 per cent reduction in hospital admissions and death in a global phase 3 trial
  • HKU molecular virologist sees the therapy as an additional treatment option for China, but says it cannot replace the key role of vaccines

Topic |   Coronavirus pandemic
China’s National Medical Products Administration granted approval for Brii Biosciences’ combination of two antibodies to be used for at-risk groups. Shutterstock Images
China’s National Medical Products Administration granted approval for Brii Biosciences’ combination of two antibodies to be used for at-risk groups. Shutterstock Images
READ FULL ARTICLE